NVO vs SEPN
NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions. SEPN: Septerna is a biotechnology company pioneering a new approach to unlock the therapeutic potential of G protein-coupled receptors (GPCRs) through oral small molecule drug discovery.
Side-by-side fundamentals
| Metric | NVO | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $39.35 | $39.35 | |
| Market cap | $174.9B | $1.8B | |
| Net margin FY2025, SEC XBRL | +33.1% | -106.4% | NVO higher |
| Gross margin FY2025, SEC XBRL | +81.0% | n/a | |
| Operating margin FY2025, SEC XBRL | +41.3% | -148.6% | NVO higher |
| ROE FY2025, SEC XBRL | +52.8% | -12.8% | NVO higher |
| ROA FY2025, SEC XBRL | +18.9% | -8.2% | NVO higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +4174.5% | |
| Revenue CAGR (3y) SEC XBRL | +20.4% | +1644.5% | SEPN higher |
| Dividend yield as of 2026-09-03 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.82 | 1.24 | |
| 1-year return as of 2026-10-20 close | -29.4% | +75.4% | SEPN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.